翰宇药业(300199) - 2024 Q4 - 年度业绩

Financial Performance - The company achieved total operating revenue of 590.20 million yuan, a year-on-year increase of 36.82%[7] - Operating loss significantly narrowed to -168.02 million yuan, improving by 66.89% year-on-year[7] - Total profit improved to -169.04 million yuan, a year-on-year increase of 66.93%[7] - Net profit attributable to shareholders was -180.42 million yuan, a 64.89% year-on-year improvement[7] - The basic earnings per share improved to -0.20 yuan, a 65.52% increase year-on-year[5] Asset and Equity Changes - The company reported a decrease in total assets to 3,001.59 million yuan, down 8.41% from the beginning of the period[5] - Shareholders' equity attributable to the company decreased to 571.86 million yuan, down 24.64%[5] Revenue Growth Drivers - The company experienced growth in overseas sales of peptide formulations and raw materials, driving overall revenue growth[8] - The improvement in operating profit margin was attributed to a shift in revenue structure towards higher-margin overseas business[8] - The company has enhanced operational efficiency, resulting in a reduction in expense ratios[8]